What Is Leukoplakia? Symptoms, Causes & Treatment

Leukoplakia is a white patch or plaque on the lining of the mouth that cannot be scraped off and cannot be attributed to any other identifiable disease. It is classified as an oral potentially malignant disorder, meaning it carries a real, if variable, risk of eventually turning into oral cancer. Most leukoplakias never become cancerous, but population data show that roughly three to five percent progress to squamous cell carcinoma within five years, and that risk climbs steeply when abnormal cell changes are already present in a biopsy.¹ Understanding what leukoplakia looks like, what drives it, and when it demands urgent attention can make a meaningful difference in outcomes.

What Leukoplakia Looks and Feels Like

Leukoplakia usually shows up as a flat, white patch somewhere inside the mouth, most often on the tongue, the inside of the cheeks, or the floor of the mouth. In its most common form, called homogeneous leukoplakia, the surface is uniformly white and either smooth or slightly wrinkled. It is typically painless, which is part of the problem: people often ignore it for weeks or months because it does not hurt.

The more worrisome form is non-homogeneous leukoplakia, where the patch has a mix of white and red coloring, sometimes called erythroleukoplakia. The surface can look speckled, nodular, or bumpy rather than flat. Non-homogeneous patches carry a higher risk of eventually becoming cancerous.² There is also a verrucous (wart-like) variant; when it spreads across multiple sites and worsens over time, clinicians call it proliferative verrucous leukoplakia, a particularly aggressive subtype discussed further below.

Some people notice a rough or leathery texture when they run their tongue over the area. Sensitivity to spicy or acidic food can develop around the patch, but outright pain is unusual unless the lesion has already undergone significant changes. Any white or mixed white-red patch in the mouth that persists for more than two weeks without an obvious explanation, such as biting the cheek or a sharp tooth edge, warrants a dental or medical evaluation.

Causes and Risk Factors

Tobacco use, in any form, is the single strongest risk factor. In one institutional study, around 80 percent of patients with leukoplakia used some form of tobacco, whether smoked or chewed.³ Smokeless tobacco products are responsible for a large share of cases, particularly in regions of South and Southeast Asia where chewing tobacco, pan, and betel quid mixtures are common. Systematic reviews consistently show a significant link between smokeless tobacco and both premalignant and malignant oral lesions.⁴

Betel quid chewing, even when the quid contains no tobacco at all, independently raises the risk. A cross-sectional study in Papua New Guinea combined with a meta-analysis found that current betel chewers had roughly four times the odds of developing leukoplakia compared to non-chewers.⁵ The areca nut in betel quid is a recognized carcinogen in its own right.

Alcohol by itself is less clearly tied to leukoplakia than tobacco is, but when the two are combined the effect is synergistic, meaning the combined risk for oral cancer is greater than you would expect by simply adding the two individual risks together.⁶ Chronic mechanical irritation from rough teeth, poorly fitting dentures, or habitual cheek-biting is sometimes blamed, though its role as an independent cause is less settled in the research. UV exposure is a recognized factor for leukoplakia of the lip, particularly the lower lip in people with heavy outdoor sun exposure.

Leukoplakia in People Who Do Not Smoke or Drink

A common misconception is that leukoplakia only happens to heavy tobacco users. While tobacco is the dominant risk factor overall, a meaningful minority of cases appear in people with no tobacco or alcohol history. This is especially striking in proliferative verrucous leukoplakia, where the majority of affected patients are non-smokers and non-drinkers.⁷

Research comparing younger and older patients with leukoplakia and related lesions has found that younger individuals (under 40) make up a small but consistent slice of cases. In a retrospective study, about one in ten patients fell into that younger group, and while fewer of them smoked compared to older patients, they still developed the condition.⁸ One counterintuitive finding from malignant transformation studies is that among patients whose leukoplakia did turn into cancer, female non-smokers and non-drinkers were overrepresented.⁹ The reasons for this are not fully understood, but it underscores why any persistent white patch deserves attention regardless of lifestyle habits.

How Leukoplakia Is Diagnosed

Leukoplakia is a clinical diagnosis of exclusion. A dentist or oral medicine specialist first rules out other conditions that can cause white patches, including oral lichen planus, thrush (candidiasis), frictional keratosis from chronic cheek-biting, and white sponge nevus. Many of these conditions look similar to the naked eye, and some require a biopsy or lab test to distinguish.¹⁰

Once a patch is provisionally identified as leukoplakia, a biopsy is the gold standard for understanding what is happening at the tissue level. Under the microscope, the tissue may show simple thickening of the outer keratin layer without any worrisome cell changes, or it may reveal dysplasia, meaning the cells are starting to look abnormal in ways that can precede cancer.¹¹ Dysplasia is typically graded as mild, moderate, or severe, and the grade matters a great deal for deciding how aggressively to treat and how closely to monitor.

Newer classification systems are incorporating a pattern called differentiated dysplasia, which looks architecturally different from the classic forms but is also associated with a high risk of progressing to cancer.¹² This is an evolving area of pathology, and it means that even biopsies initially read as “low risk” can sometimes be reclassified when examined with newer criteria.

Cancer Risk and What Drives It

The statistic most people want to know is how likely leukoplakia is to turn into cancer. A large population-based cohort study provides the clearest picture available. The overall five-year risk was about 3.3 percent. But this average hides enormous variation depending on what the biopsy shows. Leukoplakia with no dysplasia had a five-year risk of roughly 2 percent, mild dysplasia jumped to about 12 percent, and severe dysplasia reached around 32 percent.¹

A sobering detail from that same study: nearly 40 percent of the cancers that did arise came from leukoplakias that had shown no dysplasia on biopsy. This does not mean biopsies are useless. It means that a “clean” biopsy is not a guarantee, and ongoing monitoring is still necessary. Factors that tilt the odds toward malignant change include location on the tongue, non-homogeneous clinical appearance, and being female and non-smoking (which, as mentioned above, was paradoxically overrepresented in the malignant transformation group in at least one retrospective study).⁹

Proliferative Verrucous Leukoplakia

Proliferative verrucous leukoplakia (PVL) deserves its own discussion because it behaves very differently from ordinary leukoplakia. PVL typically starts as a single, unremarkable-looking white patch, then gradually spreads to multiple sites in the mouth, developing a bumpy or wart-like surface over months to years. Its cause remains unknown, and it has weak ties to tobacco and alcohol, with most patients in large series being non-smokers.¹³

What makes PVL alarming is its trajectory. A systematic review and meta-analysis covering over a thousand PVL patients found that about half experienced malignant transformation over an average follow-up of roughly six years. Women made up nearly three-quarters of the patients whose PVL became cancerous, and about a third of patients with available follow-up data died of PVL-related oral cancer.⁷ Another systematic review reported recurrence rates above 70 percent after surgery and a malignant transformation rate near 64 percent.¹⁴

Early biopsies of PVL lesions often show nothing more than simple thickening of the keratin layer, which can lull both patients and clinicians into a false sense of security. Dysplasia and carcinoma tend to develop over time, sometimes only after the lesion has been present for years.¹⁵ Because PVL is resistant to virtually every treatment and tends to recur repeatedly, current management centers on aggressive, lifelong monitoring with serial biopsies rather than any expectation of cure.

Oral Hairy Leukoplakia

Despite sharing the word “leukoplakia,” oral hairy leukoplakia is a different entity with a different cause and a very different prognosis. It appears as white, corrugated or “hairy”-textured patches, usually along the sides of the tongue, and is driven by Epstein-Barr virus (EBV) replication in the surface cells of the mouth lining. It occurs almost exclusively in people with weakened immune systems, most commonly those living with HIV.¹⁶

Unlike conventional leukoplakia, oral hairy leukoplakia is benign and does not carry a meaningful cancer risk. In HIV-positive patients, it often improves or resolves once effective antiretroviral therapy restores immune function. Its main clinical significance is as a marker of immune suppression rather than a precancerous condition in its own right.¹⁷

Treatment Options

There is no universally agreed-upon treatment for leukoplakia, and the right approach depends heavily on the biopsy findings, the type of lesion, and whether there is dysplasia. For leukoplakia without dysplasia and no high-risk features, some clinicians recommend watchful waiting with regular follow-up exams, particularly if the patient quits tobacco and the lesion begins to fade. For lesions with dysplasia or suspicious features, some form of removal is usually recommended.

Surgical and Laser Removal

The most common approach is to physically remove the patch, either with a scalpel or with a laser. A large meta-analysis pooling 80 studies and over 7,600 treated lesions found an overall recurrence rate of about 22 percent across all surgical methods. Laser-based techniques had fewer recurrences than conventional scalpel surgery or other approaches, and the combination of laser excision and vaporization appeared to be the best option for reducing recurrence.¹⁸

Among laser types, a network meta-analysis comparing multiple laser technologies and other techniques in randomized trials found that a particular erbium-chromium laser (Er,Cr:YSGG) had the lowest recurrence rates, performing significantly better than CO₂ laser, electrocautery, and standard care.¹⁹ Diode laser ablation has also shown promise: in one comparative study, none of the patients treated with diode laser experienced recurrence over four years, while 20 percent of those treated with scalpel excision did.²⁰ These are small studies, and recurrence remains an issue with every method, but the trend in the literature clearly favors laser-based approaches.

Photodynamic Therapy

Photodynamic therapy (PDT) uses a light-sensitive medication applied to the lesion, followed by exposure to a specific wavelength of light that activates the drug and destroys abnormal cells. A meta-analysis of 17 studies estimated that PDT achieves complete disappearance of the lesion in about half of patients, with a recurrence rate of roughly 13 percent.²¹ One of PDT’s advantages is that it is less invasive than surgery and can be repeated as needed. A reported case followed over ten years documented 25 PDT sessions, with a 92 percent efficacy rate for partial or complete regression and no malignant transformation during the entire follow-up period.²² PDT is increasingly seen as a useful option for long-term management, especially for lesions that recur after surgery.

Nonsurgical and Medical Treatments

Various medications have been tried over the decades, including retinoids (vitamin A derivatives), beta-carotene, and lycopene. Some of these can shrink the lesion: studies have reported clinical improvement in over half of patients treated with beta-carotene, lycopene, or vitamin A.²³ Early work with topical 13-cis-retinoic acid found that most treated patients showed at least a partial response.²⁴ The catch is that none of these medical treatments have been shown in rigorous randomized trials to prevent the lesion from eventually becoming cancerous or from recurring after treatment stops.²³ For now, medications are a supplementary tool rather than a definitive solution.

Living with a Leukoplakia Diagnosis

Being told you have a potentially precancerous lesion in your mouth can be genuinely stressful, and research has confirmed that the psychological impact is real. Patients with leukoplakia report lower quality of life compared to controls, particularly when it comes to pain, difficulty processing the diagnosis, and the burden of ongoing treatment.²⁵ The good news from longitudinal data is that quality of life tends to improve over time once patients are in an active monitoring program. Over a six-month follow-up period, patients showed significant improvement in psychological well-being, social functioning, and their perception of how treatment affected daily life.²⁶ Feeling in control of the monitoring process and having a clear follow-up schedule seem to help.

If you smoke or use tobacco in any form, quitting is the single most impactful step you can take. Many tobacco-related leukoplakias shrink or disappear entirely after cessation, though this is not guaranteed and the lesion still needs follow-up even if it fades. Reducing alcohol intake, maintaining good oral hygiene, and addressing sources of chronic irritation like rough dental work are all reasonable supportive measures.

The Oral Microbiome and Leukoplakia

An emerging area of research is the relationship between the community of bacteria in the mouth and the development or progression of leukoplakia. Animal models have shown that as leukoplakia develops, the composition of oral bacteria shifts significantly, with certain species increasing in abundance while others decline. These shifts occur alongside spikes in inflammatory markers, suggesting a feedback loop between microbial imbalance and tissue damage.²⁷

In the context of proliferative verrucous leukoplakia specifically, bacterial genera such as Fusobacterium and Porphyromonas have been linked to biofilm formation and modulation of the signals that control how surface cells grow and divide.²⁸ This research is still in early stages, and no one is prescribing probiotics for leukoplakia patients. But it opens the door to potential future screening tools or therapeutic targets. Salivary biomarkers are another area of active investigation; at least one study has found that levels of ferritin and total protein in saliva differ between patients with oral potentially malignant disorders and healthy controls, raising the possibility that a simple saliva test could one day complement or partially replace biopsy for screening purposes.²⁹ For now, AI-assisted analysis of cell samples is also being explored as a way to monitor treated leukoplakia over time without repeated invasive biopsies.³⁰

1
PubMed Central. Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study
2
PMC Central. A clinical diagnosis of oral leukoplakia; A guide for dentists
3
PubMed Central. Analysis of Oral Leukoplakia and Tobacco-Related Habits in Population of Chengalpattu District- An Institution-Based Retrospective Study
4
PubMed Central. Association between Smokeless Tobacco and risk of malignant and premalignant conditions of oral cavity: A systematic review of Indian literature
5
PubMed. Betel quid not containing tobacco and oral leukoplakia: a report on a cross-sectional study in Papua New Guinea and a meta-analysis of current evidence
6
PubMed Central. Effect of tobacco in human oral leukoplakia: a cytomorphometric analysis
7
PubMed Central. Malignant transformation of proliferative Verrucous Leukoplakia-systematic review & meta-analysis
8
PubMed Central. Leukoplakia and erythroplakia in youngers versus older individuals: a clinicopathological retrospective study
9
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. Malignant transformation of oral leukoplakia and associated risk factors: A retrospective clinical study from a single institution
10
PubMed Central. White, red, and mixed lesions of oral mucosa: A clinicopathologic approach to diagnosis
11
Journal of Oral and Maxillofacial Surgery. Leukoplakia—A Diagnostic and Management Algorithm
12
PubMed. Oral leukoplakia classification and staging system with incorporation of differentiated dysplasia
13
PubMed Central. Proliferative verrucous leukoplakia: diagnosis management and current advances
14
PubMed. Optimal Management of Proliferative Verrucous Leukoplakia: A Systematic Review of the Literature
15
PubMed Central. Oral Epithelial Dysplasia and Premalignancy
16
PubMed Central. Epstein-Barr Virus and Its Association with Oral Hairy Leukoplakia: A Short Review
17
PubMed. Epstein Barr Virus detection and latent membrane protein 1 in oral hairy leukoplakia in HIV+ Venezuelan patients
18
PubMed Central. Recurrence in Oral Leukoplakia: A Systematic Review and Meta-analysis
19
PubMed Central. Laser therapy decreases oral leukoplakia recurrence and boosts patient comfort: a network meta-analysis and systematic review
20
Journal of Indian Academy of Oral Medicine and Radiology. A comparative evaluation of diode laser ablation versus scalpel excision for management of oral leukoplakia
21
PubMed Central. Photodynamic therapy (PDT) for oral leukoplakia: a systematic review and meta-analysis of single-arm studies examining efficacy and subgroup analyses
22
PubMed. Photodynamic therapy for long-term management of oral leukoplakia: A 10-year follow-up case report
23
PubMed Central. A review of the nonsurgical treatment of oral leukoplakia
24
PubMed. Effect of retinoids on oral leukoplakia
25
Journal of Oral Pathology and Medicine. Quality of life in patients with oral leukoplakia
26
PubMed. Changes in quality of life over time in patients diagnosed with oral leukoplakia: A prospective longitudinal study
27
PubMed Central. Decoding oral leukoplakia: microbiome dysbiosis and inflammatory dynamics unveiled in a rat model
28
PubMed. Microbial dysbiosis and host-microbe interactions in proliferative verrucous leukoplakia: insights into carcinogenic potential
29
PubMed Central. Salivary Biomarkers in Patients with Oral Potentially Malignant Disorders (OPMD): A Case–Control Study
30
PubMed. Continuous artificial intelligence-assisted DNA aneuploidy cytology for surveilling dysplastic oral leukoplakia treated by photodynamic therapy